Drug Profile

Research programme: neuroplastogens - AbbVie/Gilgamesh Pharmaceuticals

Alternative Names: Neuroplastogens - Gilgamesh Pharmaceuticals/AbbVie

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilgamesh Pharmaceuticals
Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 Oct 2025 Preclinical trials in Anxiety disorders in USA (PO) (Gilgamesh Pharmaceuticals pipeline, October 2025)
09 Oct 2025 Preclinical trials in Depressive disorders in USA (PO) (Gilgamesh Pharmaceuticals pipeline, October 2025)
13 May 2024 AbbVie and Gilgamesh Pharmaceuticals enters into a research and development agreement to develop next-generation therapies for psychiatric disorders

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com